Association between Serum Lipids and Antipsychotic Response in Schizophrenia

Current Neuropharmacology
David D KimRic M Procyshyn

Abstract

Metabolic abnormalities are serious health problems in individuals with schizophrenia. Paradoxically, studies have noted an association where individuals who gained body weight or who have increased their serum lipids demonstrated a better antipsychotic response. As serum lipids serve as more specific physiological markers than body weight, the objective of this study was to review studies that examined the association between changes in serum lipids and changes in symptoms during antipsychotic treatment in individuals with schizophrenia. A Medline® literature search was performed. Fourteen studies were included and analyzed. Evidence suggests that increases in serum lipids may be associated with decreases in symptoms during antipsychotic treatment. This inverse association may be independent of confounding variables, such as weight gain, and may be most evident during treatment with clozapine. Also, according to recent randomized controlled trials, lipid-lowering agents do not appear to worsen symptoms although this needs to be further investigated in clozapine-treated patients. Future studies should investigate the association in question in a larger population and identify underlying mechanisms.

References

Aug 25, 1997·The Journal of Cell Biology·B DehouckR Cecchelli
Jun 1, 2001·The American Journal of Psychiatry·R M ProcyshynK M Wasan
Jul 20, 2002·International Clinical Psychopharmacology·S PandeK Chow
May 21, 2003·The Journal of Clinical Psychiatry·Murad AtmacaBilal Ustundag
Nov 13, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·George GaryfallosKostas Fokas
Nov 14, 2007·The Australian and New Zealand Journal of Psychiatry·Marie-Josée PoulinAngelo Tremblay
Feb 6, 2009·The Journal of Clinical Psychiatry·Luca MascitelliMark R Goldstein
Mar 19, 2009·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Marc DE HertRuud VAN Winkel
Oct 29, 2009·JAMA : the Journal of the American Medical Association·Christoph U CorrellAnil K Malhotra
Feb 22, 2011·Schizophrenia Research·Eric HermesRobert Rosenheck
Mar 18, 2011·Current Opinion in Lipidology·De-xiu BuAndrew H Lichtman
Jan 18, 2013·Journal of Psychopharmacology·John LallyColm McDonald
Jul 19, 2013·Current Cardiovascular Risk Reports·Donna J LangRic M Procyshyn
Oct 31, 2013·International Clinical Psychopharmacology·Lurdes TseAlasdair M Barr
Dec 3, 2014·Asian Journal of Psychiatry·Eesha SharmaBangalore N Gangadhar
Jan 30, 2015·European Journal of Clinical Pharmacology·Z WhitneyA M Barr
Oct 10, 2015·Nordic Journal of Psychiatry·Evgeny ChukhinGrigori Joffe
Oct 29, 2015·JAMA Psychiatry·Mark OlfsonT Scott Stroup
Dec 13, 2016·International Clinical Psychopharmacology·Soode Tajik-EsmaeeliShahin Akhondzadeh
Feb 23, 2017·Journal of Clinical Psychopharmacology·David D KimRic M Procyshyn
Mar 24, 2018·Psychiatry Research·David D KimRic M Procyshyn
Apr 20, 2018·Frontiers in Neuroscience·Jessica W Y YuenAlasdair M Barr

❮ Previous
Next ❯

Citations

Nov 13, 2020·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Paweł WójciakJanusz K Rybakowski
Dec 19, 2020·Frontiers in Psychiatry·Heidi N BoydaAlasdair M Barr
Mar 16, 2021·Frontiers in Endocrinology·Jessica W Y YuenAlasdair M Barr
Jun 21, 2020·Current Neuropharmacology·Yuyou HuangZiping Han

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

British Medical Bulletin
John Lally, James H MacCabe
The Journal of Clinical Psychiatry
Daniel E Casey
Journal of Psychiatry & Neuroscience : JPN
Ric M ProcyshynClozapine and Risperidone Enhancement Study Group
Expert Opinion on Drug Safety
Felix-Martin Werner, Rafael Coveñas
© 2022 Meta ULC. All rights reserved